Global COVID-19 Recombinant Protein Vaccine Market Research Report 2023

Publication ID:

PB504244480

Publication Date:

May 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.
Highlights
The global COVID-19 Recombinant Protein Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for COVID-19 Recombinant Protein Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for COVID-19 Recombinant Protein Vaccine in Pharmaceutical And Biotechnology Companies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of COVID-19 Recombinant Protein Vaccine include GSK, Johnson & Johnson, Sanofi, Novavax, Pukang Biologic Technology, Clover Biopharmaceuticals and Suzhou Yuzhibo Biotechnology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for COVID-19 Recombinant Protein Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Recombinant Protein Vaccine.
The COVID-19 Recombinant Protein Vaccine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global COVID-19 Recombinant Protein Vaccine market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the COVID-19 Recombinant Protein Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Segment by Type
Being Developed
Preclinical
Clinical I
Clinical II
Segment by Application
Pharmaceutical And Biotechnology Companies
Hospital
Academic And Research Organizations
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COVID-19 Recombinant Protein Vaccine companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global COVID-19 Recombinant Protein Vaccine Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Being Developed
1.2.3 Preclinical
1.2.4 Clinical I
1.2.5 Clinical II
1.3 Market by Application
1.3.1 Global COVID-19 Recombinant Protein Vaccine Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical And Biotechnology Companies
1.3.3 Hospital
1.3.4 Academic And Research Organizations
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global COVID-19 Recombinant Protein Vaccine Market Perspective (2018-2029)
2.2 COVID-19 Recombinant Protein Vaccine Growth Trends by Region
2.2.1 Global COVID-19 Recombinant Protein Vaccine Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 COVID-19 Recombinant Protein Vaccine Historic Market Size by Region (2018-2023)
2.2.3 COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Region (2024-2029)
2.3 COVID-19 Recombinant Protein Vaccine Market Dynamics
2.3.1 COVID-19 Recombinant Protein Vaccine Industry Trends
2.3.2 COVID-19 Recombinant Protein Vaccine Market Drivers
2.3.3 COVID-19 Recombinant Protein Vaccine Market Challenges
2.3.4 COVID-19 Recombinant Protein Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top COVID-19 Recombinant Protein Vaccine Players by Revenue
3.1.1 Global Top COVID-19 Recombinant Protein Vaccine Players by Revenue (2018-2023)
3.1.2 Global COVID-19 Recombinant Protein Vaccine Revenue Market Share by Players (2018-2023)
3.2 Global COVID-19 Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by COVID-19 Recombinant Protein Vaccine Revenue
3.4 Global COVID-19 Recombinant Protein Vaccine Market Concentration Ratio
3.4.1 Global COVID-19 Recombinant Protein Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by COVID-19 Recombinant Protein Vaccine Revenue in 2022
3.5 COVID-19 Recombinant Protein Vaccine Key Players Head office and Area Served
3.6 Key Players COVID-19 Recombinant Protein Vaccine Product Solution and Service
3.7 Date of Enter into COVID-19 Recombinant Protein Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 COVID-19 Recombinant Protein Vaccine Breakdown Data by Type
4.1 Global COVID-19 Recombinant Protein Vaccine Historic Market Size by Type (2018-2023)
4.2 Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Type (2024-2029)
5 COVID-19 Recombinant Protein Vaccine Breakdown Data by Application
5.1 Global COVID-19 Recombinant Protein Vaccine Historic Market Size by Application (2018-2023)
5.2 Global COVID-19 Recombinant Protein Vaccine Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America COVID-19 Recombinant Protein Vaccine Market Size (2018-2029)
6.2 North America COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
6.4 North America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe COVID-19 Recombinant Protein Vaccine Market Size (2018-2029)
7.2 Europe COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
7.4 Europe COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size (2018-2029)
8.2 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2018-2023)
8.4 Asia-Pacific COVID-19 Recombinant Protein Vaccine Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America COVID-19 Recombinant Protein Vaccine Market Size (2018-2029)
9.2 Latin America COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
9.4 Latin America COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size (2018-2029)
10.2 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2018-2023)
10.4 Middle East & Africa COVID-19 Recombinant Protein Vaccine Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK COVID-19 Recombinant Protein Vaccine Introduction
11.1.4 GSK Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Introduction
11.2.4 Johnson & Johnson Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Introduction
11.3.4 Sanofi Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Novavax
11.4.1 Novavax Company Detail
11.4.2 Novavax Business Overview
11.4.3 Novavax COVID-19 Recombinant Protein Vaccine Introduction
11.4.4 Novavax Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.4.5 Novavax Recent Development
11.5 Pukang Biologic Technology
11.5.1 Pukang Biologic Technology Company Detail
11.5.2 Pukang Biologic Technology Business Overview
11.5.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Introduction
11.5.4 Pukang Biologic Technology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.5.5 Pukang Biologic Technology Recent Development
11.6 Clover Biopharmaceuticals
11.6.1 Clover Biopharmaceuticals Company Detail
11.6.2 Clover Biopharmaceuticals Business Overview
11.6.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Introduction
11.6.4 Clover Biopharmaceuticals Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.6.5 Clover Biopharmaceuticals Recent Development
11.7 Suzhou Yuzhibo Biotechnology
11.7.1 Suzhou Yuzhibo Biotechnology Company Detail
11.7.2 Suzhou Yuzhibo Biotechnology Business Overview
11.7.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Introduction
11.7.4 Suzhou Yuzhibo Biotechnology Revenue in COVID-19 Recombinant Protein Vaccine Business (2018-2023)
11.7.5 Suzhou Yuzhibo Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

GSK
Johnson & Johnson
Sanofi
Novavax
Pukang Biologic Technology
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂